Prudent Man Advisors LLC Sells 192 Shares of Incyte Co. (NASDAQ:INCY)

Prudent Man Advisors LLC lowered its holdings in Incyte Co. (NASDAQ:INCYFree Report) by 2.8% during the third quarter, Holdings Channel.com reports. The firm owned 6,641 shares of the biopharmaceutical company’s stock after selling 192 shares during the period. Prudent Man Advisors LLC’s holdings in Incyte were worth $384,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Clear Street Markets LLC raised its position in Incyte by 93.6% in the 1st quarter. Clear Street Markets LLC now owns 362 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 175 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in Incyte by 91.0% in the first quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 213 shares during the last quarter. Glassman Wealth Services increased its position in Incyte by 49.9% in the second quarter. Glassman Wealth Services now owns 640 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 213 shares during the period. Massmutual Trust Co. FSB ADV raised its holdings in Incyte by 132.9% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 757 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 432 shares during the last quarter. Finally, Salem Investment Counselors Inc. lifted its position in Incyte by 1,458.0% during the 2nd quarter. Salem Investment Counselors Inc. now owns 779 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 729 shares during the period. Institutional investors own 92.61% of the company’s stock.

Incyte Stock Up 0.5 %

INCY stock opened at $57.66 on Monday. The business has a 50-day moving average of $61.03 and a 200-day moving average of $59.83. Incyte Co. has a fifty-two week low of $50.27 and a fifty-two week high of $81.08. The stock has a market capitalization of $12.92 billion, a P/E ratio of 30.51, a P/E/G ratio of 0.63 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.91 and a quick ratio of 3.86.

Insider Buying and Selling at Incyte

In related news, EVP Vijay K. Iyengar sold 657 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $65.00, for a total transaction of $42,705.00. Following the completion of the transaction, the executive vice president now owns 43,412 shares in the company, valued at $2,821,780. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 17.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on INCY. Morgan Stanley dropped their price target on shares of Incyte from $74.00 to $64.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 1st. Mizuho decreased their price objective on Incyte from $82.00 to $77.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Truist Financial reissued a “buy” rating and issued a $91.00 target price on shares of Incyte in a research note on Wednesday, November 29th. The Goldman Sachs Group cut Incyte from a “buy” rating to a “neutral” rating and lowered their price target for the company from $98.00 to $65.00 in a research note on Tuesday, November 21st. Finally, William Blair reaffirmed an “outperform” rating on shares of Incyte in a research note on Tuesday, February 6th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $78.67.

Get Our Latest Report on INCY

Incyte Profile

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Stories

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.